Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic
potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.